{"id":"https://openalex.org/W4417018564","doi":"https://doi.org/10.1182/blood-2025-5663","title":"Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up","display_name":"Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up","publication_year":2025,"publication_date":"2025-11-03","ids":{"openalex":"https://openalex.org/W4417018564","doi":"https://doi.org/10.1182/blood-2025-5663"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2025-5663","doi":"https://doi.org/10.1182/blood-2025-5663","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2025-5663","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051296565","display_name":"Mazyar S. Shadman","orcid":"https://orcid.org/0000-0002-3365-6562","observed_orcids":["https://orcid.org/0000-0002-3365-6562"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mazyar Shadman","raw_affiliation_strings":["1Fred Hutchinson Cancer Center, Seattle, United States","2University of Washington, Seattle, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Fred Hutchinson Cancer Center, Seattle, United States","institution_ids":["https://openalex.org/I4210089486"]},{"raw_affiliation_string":"2University of Washington, Seattle, United States","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000959540","display_name":"Ian W. Flinn","orcid":"https://orcid.org/0000-0001-6724-290X","observed_orcids":["https://orcid.org/0000-0001-6724-290X"]},"institutions":[{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ian Flinn","raw_affiliation_strings":["3Tennessee Oncology/OneOncology, Nashville, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Tennessee Oncology/OneOncology, Nashville, United States","institution_ids":["https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036543091","display_name":"Moshe Yair Levy","orcid":"https://orcid.org/0000-0002-2570-6128","observed_orcids":["https://orcid.org/0000-0002-2570-6128"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Moshe Levy","raw_affiliation_strings":["4Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035860475","display_name":"Steven W. Papish","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Steven Papish","raw_affiliation_strings":["5Summit Medical Group-MD Anderson Cancer Center, Morristown, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Summit Medical Group-MD Anderson Cancer Center, Morristown, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061916244","display_name":"John M. Burke","orcid":"https://orcid.org/0000-0002-5144-6710","observed_orcids":["https://orcid.org/0000-0002-5144-6710"]},"institutions":[{"id":"https://openalex.org/I4210140702","display_name":"Rocky Mountain Cancer Centers","ror":"https://ror.org/03ynhs115","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210140702"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John M. Burke","raw_affiliation_strings":["6Rocky Mountain Cancer Centers, US Oncology Research, Aurora, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Rocky Mountain Cancer Centers, US Oncology Research, Aurora, United States","institution_ids":["https://openalex.org/I4210140702"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055078293","display_name":"Jamal Ghazi Misleh","orcid":"https://orcid.org/0009-0004-7747-0948","observed_orcids":["https://orcid.org/0009-0004-7747-0948"]},"institutions":[{"id":"https://openalex.org/I4210114433","display_name":"Medical Oncology Hematology Consultants","ror":"https://ror.org/01yx43d58","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210114433"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jamal Misleh","raw_affiliation_strings":["7Medical Oncology Hematology Consultants, Newark, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Medical Oncology Hematology Consultants, Newark, United States","institution_ids":["https://openalex.org/I4210114433"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069917831","display_name":"Jennifer L. Cultrera","orcid":"https://orcid.org/0009-0007-4823-4622","observed_orcids":["https://orcid.org/0009-0007-4823-4622"]},"institutions":[{"id":"https://openalex.org/I4210118420","display_name":"Florida Cancer Specialists & Research Institute","ror":"https://ror.org/02px37122","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210118420"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Cultrera","raw_affiliation_strings":["8Florida Cancer Specialists & Research Institute, Leesburg, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Florida Cancer Specialists & Research Institute, Leesburg, United States","institution_ids":["https://openalex.org/I4210118420"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024431512","display_name":"Habte Aragaw Yimer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Habte Yimer","raw_affiliation_strings":["9Texas Oncology-Tyler, US Oncology Research, Tyler, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Texas Oncology-Tyler, US Oncology Research, Tyler, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033508968","display_name":"Edwin C. Kingsley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210163348","display_name":"Comprehensive Cancer Centers of Nevada","ror":"https://ror.org/05etxbz89","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210163348"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edwin Kingsley","raw_affiliation_strings":["10Comprehensive Cancer Centers of Nevada, Las Vegas, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Comprehensive Cancer Centers of Nevada, Las Vegas, United States","institution_ids":["https://openalex.org/I4210163348"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042998970","display_name":"Charles Michael Farber","orcid":"https://orcid.org/0000-0002-2753-6986","observed_orcids":["https://orcid.org/0000-0002-2753-6986"]},"institutions":[{"id":"https://openalex.org/I2802646204","display_name":"Morristown Medical Center","ror":"https://ror.org/03m6tev69","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2802646204","https://openalex.org/I67339987"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles Farber","raw_affiliation_strings":["11Atlantic Hematology Oncology, Morristown Medical Center, Morristown, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Atlantic Hematology Oncology, Morristown Medical Center, Morristown, United States","institution_ids":["https://openalex.org/I2802646204"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082174340","display_name":"James Thomas D'Olimpio","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James D'Olimpio","raw_affiliation_strings":["12Clinical Research Alliance, Westbury, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12Clinical Research Alliance, Westbury, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Nan Sun","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nan Sun","raw_affiliation_strings":["13BeOne Medicines Ltd, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"13BeOne Medicines Ltd, Shanghai, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009491576","display_name":"Adam Idoine","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Adam Idoine","raw_affiliation_strings":["14BeOne Medicines Ltd, San Carlos, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"14BeOne Medicines Ltd, San Carlos, United States","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5013007045","display_name":"Jeff Porter Sharman","orcid":"https://orcid.org/0000-0001-5611-6115","observed_orcids":["https://orcid.org/0000-0001-5611-6115"]},"institutions":[{"id":"https://openalex.org/I4210148213","display_name":"Willamette Valley Cancer Institute and Research Center","ror":"https://ror.org/05jr8e497","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210148213"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeff Sharman","raw_affiliation_strings":["15Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"15Willamette Valley Cancer Institute and Research Center, US Oncology Research, Eugene, United States","institution_ids":["https://openalex.org/I4210148213"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"146","issue":"Supplement 1","first_page":"5663","last_page":"5663"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11899","display_name":"Brucella: diagnosis, epidemiology, treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3404","display_name":"Small Animals"},"field":{"id":"https://openalex.org/fields/34","display_name":"Veterinary"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/zanubrutinib","display_name":"zanubrutinib","score":1.0},{"id":"https://openalex.org/keywords/b-cell-malignancies","display_name":"B-cell malignancies","score":0.8180000185966492},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.9739999771118164},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.8399999737739563},{"id":"https://openalex.org/keywords/waldenstrom-macroglobulinemia","display_name":"Waldenstr\u00f6m macroglobulinemia","score":0.9599999785423279},{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/marginal-zone-lymphoma","display_name":"marginal zone lymphoma","score":1.0},{"id":"https://openalex.org/keywords/long-term-safety","display_name":"long-term safety","score":0.6290000081062317},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.6039999723434448},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5360000133514404},{"id":"https://openalex.org/keywords/relapse-free-survival","display_name":"relapse-free survival","score":0.5509999990463257},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7620000243186951},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.5139999985694885},{"id":"https://openalex.org/keywords/btk-inhibitor-resistance","display_name":"BTK inhibitor resistance","score":0.3230000138282776}],"concepts":[{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.9187999963760376},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7554000020027161},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6935999989509583},{"id":"https://openalex.org/C90059517","wikidata":"https://www.wikidata.org/wiki/Q423572","display_name":"Bruton's tyrosine kinase","level":4,"score":0.6850000023841858},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.589900016784668},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5087000131607056},{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.491100013256073},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.39809998869895935},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3865000009536743},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.3831999897956848},{"id":"https://openalex.org/C2781038049","wikidata":"https://www.wikidata.org/wiki/Q1778287","display_name":"Waldenstrom macroglobulinemia","level":3,"score":0.38029998540878296},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.3785000145435333},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.3652999997138977},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.3488999903202057},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3379000127315521},{"id":"https://openalex.org/C2778559949","wikidata":"https://www.wikidata.org/wiki/Q2626074","display_name":"Diffuse large B-cell lymphoma","level":3,"score":0.32989999651908875},{"id":"https://openalex.org/C2776391228","wikidata":"https://www.wikidata.org/wiki/Q4118092","display_name":"Macroglobulinemia","level":3,"score":0.2851000130176544},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.27309998869895935},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.2694999873638153},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.259799987077713},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.25859999656677246},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.25369998812675476},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.2502000033855438}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2025-5663","doi":"https://doi.org/10.1182/blood-2025-5663","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2025-5663","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":[],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"While":[2],"Bruton":[3],"tyrosine":[4],"kinase":[5],"(BTK)":[6],"inhibitors":[7],"are":[8],"a":[9,60,240,408,424,516,571,590],"mainstay":[10],"of":[11,29,106,126,128,133,138,171,200,210,217,242,261,272,277,436,486,531,556,575],"treatment":[12,35,279,543,566,594],"for":[13,169],"B-cell":[14,103],"malignancies,":[15],"their":[16,441],"use":[17],"can":[18,533],"be":[19,589],"limited":[20],"by":[21,206],"adverse":[22],"events":[23,338,350,383,401,560],"(AEs).":[24],"In":[25,501,580],"clinical":[26],"trials,":[27],"15%-23%":[28],"patients":[30,101,136,145,215,250,300,307,428,459,513,527],"treated":[31],"with":[32,76,81,102,122,146,188,398,404,414,455,465,479,496,511,528,545,548],"acalabrutinib":[33,109,139,172,201,219,263,336,348,381,390,442,468,532,550,558],"discontinued":[34,309,429],"due":[36,311,431],"to":[37,69,255,312,432,440,538,567,586],"AEs":[38],"(Sharman":[39],"JP,":[40],"et":[41,48,54,112],"al.":[42,49,55,113],"Blood.":[43,56],"2023;142(Suppl":[44],"1):636;":[45],"Ghia":[46],"P,":[47],"Hemasphere.":[50],"2022;6(12):e801;":[51],"Seymour":[52],"JF,":[53],"2023;142(8):687-699).":[57],"Zanubrutinib":[58],"is":[59],"highly":[61],"potent":[62],"and":[63,131,196,248,285,356,361,365,367,421,446,469,535,592],"selective":[64],"next-generation":[65],"BTK":[66,71,83,190,499],"inhibitor":[67,191],"designed":[68],"maximize":[70],"occupancy,":[72],"providing":[73],"greater":[74],"efficacy":[75,132],"fewer":[77],"off-target":[78],"bindings":[79],"compared":[80,547],"other":[82],"inhibitors.":[84,500],"Previous":[85],"data":[86,297,524],"from":[87],"this":[88],"phase":[89],"2":[90,243],"study":[91,288],"(BGB-3111-215;":[92],"NCT04116437)":[93],"showed":[94],"that":[95,412,438,526],"zanubrutinib":[96,134,174,221,278,310,405,430,480,546,568,587],"was":[97,233,264,280,290,509],"well":[98],"tolerated":[99],"in":[100,135,570,577,582],"malignancies":[104],"intolerant":[105,137,216,254],"ibrutinib":[107,470],"and/or":[108],"(Shadman":[110],"M,":[111],"Lancet":[114],"Haematol.":[115],"2023;10[1]:e35-e45).":[116],"Here,":[117],"we":[118],"report":[119],"long-term":[120],"results,":[121],"3":[123,494,498],"additional":[124],"years":[125],"follow-up,":[127],"the":[129,270,274,286,296,342,388,418,433,451,461,487,505],"tolerability":[130],"(study":[140],"cohort":[141],"2).":[142],"Methods:":[143],"Eligible":[144],"chronic":[147],"lymphocytic":[148,150],"leukemia/small":[149],"lymphoma":[151,158,163],"(CLL/SLL),":[152],"Waldenstr\u00f6m":[153],"macroglobulinemia":[154],"(WM),":[155],"mantle":[156],"cell":[157],"(MCL),":[159],"or":[160,179,331,481],"marginal":[161],"zone":[162],"(MZL)":[164],"who":[165],"met":[166],"protocol-defined":[167],"criteria":[168],"intolerance":[170,202,337,349,382,391,463,530,559],"received":[173,220,239],"160":[175],"mg":[176,181],"twice":[177],"daily":[178],"320":[180],"once":[182],"daily.":[183],"Patients":[184,238],"whose":[185],"disease":[186,329,506,572],"progressed":[187],"prior":[189,218,244,256,262,456,467,529,549,557],"therapy":[192],"were":[193,204,252,302,339,351],"excluded.":[194],"Safety":[195],"efficacy,":[197],"including":[198],"recurrence":[199,478,485],"events,":[203,392],"evaluated":[205],"investigators.":[207],"Results:":[208],"As":[209],"May":[211],"1,":[212],"2025,":[213],"39":[214,343,373,502],"(CLL/SLL,":[222],"n=30;":[223],"WM,":[224],"n=4;":[225],"MCL,":[226],"n=3;":[227],"MZL,":[228],"n=2).":[229],"The":[230,258,345],"median":[231,241,259,275,287,542],"age":[232],"71":[234],"(range,":[235,246,266,282,292],"51-87)":[236],"years.":[237],"therapies":[245],"1-6),":[247],"14":[249],"(36%)":[251],"also":[253],"ibrutinib.":[257],"duration":[260,276,544],"5.7":[265,553],"0.2-68.6)":[267],"months.":[268,294],"At":[269,295],"time":[271],"analysis,":[273],"18.2":[281],"0.5-55.8)":[283],"months,":[284],"follow-up":[289],"28.5":[291],"1.9-55.8)":[293],"cut-off,":[298],"25":[299],"(64%)":[301],"still":[303],"on":[304,385],"zanubrutinib.":[305,386,399,539],"Fourteen":[306],"had":[308,475,492],"AE":[313],"(n=7;":[314],"diarrhea":[315,366,495],"[n=2],":[316],"rash,":[317,445],"skin":[318],"toxicity,":[319],"neutropenia,":[320],"fall,":[321],"myalgia":[322,352],"[n=1":[323],"each]),":[324],"physician":[325],"decision":[326],"(n=4),":[327],"progressive":[328],"(n=2),":[330],"withdrawal":[332],"(n=1).":[333],"Overall,":[334],"55":[335,389],"reported":[340],"among":[341],"patients.":[344,579],"most":[346],"common":[347],"(n=8":[353],"events),":[354],"arthralgia":[355],"headache":[357],"(n=7":[358],"each),":[359,364],"rash":[360],"fatigue":[362],"(n=4":[363],"hemorrhage":[368],"(n=3":[369],"each).":[370],"Of":[371,387,472],"these":[372],"patients,":[374,504,584],"24":[375],"(62%)":[376],"did":[377,395,561],"not":[378,396,562],"have":[379],"any":[380],"recur":[384,397],"37":[393],"(67%)":[394],"Eighteen":[400],"(33%)":[402],"recurred":[403,449],"(0":[406],"at":[407,417,423,450],"higher":[409],"grade":[410,453,483,493],"than":[411,519],"observed":[413],"acalabrutinib,":[415],"11":[416],"same":[419,434,452,462,488],"grade,":[420],"7":[422],"lower":[425],"grade).":[426],"Three":[427],"type":[435],"event":[437,464],"led":[439],"discontinuation":[443],"(myalgia,":[444],"diarrhea;":[447],"all":[448,497],"as":[454],"acalabrutinib).":[457],"Five":[458],"experienced":[460],"both":[466],"treatment.":[471],"these,":[473],"4":[474],"either":[476],"no":[477],"only":[482],"1":[484],"event.":[489],"One":[490],"patient":[491],"efficacy-evaluable":[503,578],"control":[507,573],"rate":[508,574],"92.3%,":[510],"22":[512],"(56.4%)":[514],"having":[515],"response":[517],"better":[518],"stable":[520],"disease.":[521],"Conclusions:":[522],"These":[523],"demonstrate":[525],"safely":[534],"efficaciously":[536],"switch":[537],"Despite":[540],"longer":[541],"(18.2":[551],"vs":[552],"months),":[554],"67%":[555],"recur.":[563],"Furthermore,":[564],"switching":[565,585],"resulted":[569],"92%":[576],"summary,":[581],"acalabrutinib-intolerant":[583],"may":[588],"well-tolerated":[591],"effective":[593],"option.":[595]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2025-12-05T00:00:00"}